255 related articles for article (PubMed ID: 26992070)
1. High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients' sera.
Ritz D; Gloger A; Weide B; Garbe C; Neri D; Fugmann T
Proteomics; 2016 May; 16(10):1570-80. PubMed ID: 26992070
[TBL] [Abstract][Full Text] [Related]
2. Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
Gloger A; Ritz D; Fugmann T; Neri D
Cancer Immunol Immunother; 2016 Nov; 65(11):1377-1393. PubMed ID: 27600516
[TBL] [Abstract][Full Text] [Related]
3. Soluble HLA peptidome of pleural effusions is a valuable source for tumor antigens.
Khazan-Kost S; Cafri G; Melamed Kadosh D; Mooshayef N; Chatterji S; Dominissini D; Manor S; Zisser B; Broday L; Talalai E; Shemer A; Zadok O; Ofek E; Onn A; Admon A; Peled M
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580925
[TBL] [Abstract][Full Text] [Related]
4. Soluble plasma HLA peptidome as a potential source for cancer biomarkers.
Bassani-Sternberg M; Barnea E; Beer I; Avivi I; Katz T; Admon A
Proc Natl Acad Sci U S A; 2010 Nov; 107(44):18769-76. PubMed ID: 20974924
[TBL] [Abstract][Full Text] [Related]
5. Purification of soluble HLA class I complexes from human serum or plasma deliver high quality immuno peptidomes required for biomarker discovery.
Ritz D; Gloger A; Neri D; Fugmann T
Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27862975
[TBL] [Abstract][Full Text] [Related]
6. Exploration of peptides bound to MHC class I molecules in melanoma.
Pritchard AL; Hastie ML; Neller M; Gorman JJ; Schmidt CW; Hayward NK
Pigment Cell Melanoma Res; 2015 May; 28(3):281-94. PubMed ID: 25645385
[TBL] [Abstract][Full Text] [Related]
7. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.
Shraibman B; Barnea E; Kadosh DM; Haimovich Y; Slobodin G; Rosner I; López-Larrea C; Hilf N; Kuttruff S; Song C; Britten C; Castle J; Kreiter S; Frenzel K; Tatagiba M; Tabatabai G; Dietrich PY; Dutoit V; Wick W; Platten M; Winkler F; von Deimling A; Kroep J; Sahuquillo J; Martinez-Ricarte F; Rodon J; Lassen U; Ottensmeier C; van der Burg SH; Thor Straten P; Poulsen HS; Ponsati B; Okada H; Rammensee HG; Sahin U; Singh H; Admon A
Mol Cell Proteomics; 2019 Jun; 18(6):1255-1268. PubMed ID: 31154438
[TBL] [Abstract][Full Text] [Related]
8. Large scale mass spectrometric profiling of peptides eluted from HLA molecules reveals N-terminal-extended peptide motifs.
Escobar H; Crockett DK; Reyes-Vargas E; Baena A; Rockwood AL; Jensen PE; Delgado JC
J Immunol; 2008 Oct; 181(7):4874-82. PubMed ID: 18802091
[TBL] [Abstract][Full Text] [Related]
9. Discrimination Between Human Leukocyte Antigen Class I-Bound and Co-Purified HIV-Derived Peptides in Immunopeptidomics Workflows.
Partridge T; Nicastri A; Kliszczak AE; Yindom LM; Kessler BM; Ternette N; Borrow P
Front Immunol; 2018; 9():912. PubMed ID: 29780384
[TBL] [Abstract][Full Text] [Related]
10. Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.
Shraibman B; Barnea E; Kadosh DM; Haimovich Y; Slobodin G; Rosner I; López-Larrea C; Hilf N; Kuttruff S; Song C; Britten C; Castle J; Kreiter S; Frenzel K; Tatagiba M; Tabatabai G; Dietrich PY; Dutoit V; Wick W; Platten M; Winkler F; von Deimling A; Kroep J; Sahuquillo J; Martinez-Ricarte F; Rodon J; Lassen U; Ottensmeier C; van der Burg SH; Thor Straten P; Poulsen HS; Ponsati B; Okada H; Rammensee HG; Sahin U; Singh H; Admon A
Mol Cell Proteomics; 2018 Nov; 17(11):2132-2145. PubMed ID: 30072578
[TBL] [Abstract][Full Text] [Related]
11. A large peptidome dataset improves HLA class I epitope prediction across most of the human population.
Sarkizova S; Klaeger S; Le PM; Li LW; Oliveira G; Keshishian H; Hartigan CR; Zhang W; Braun DA; Ligon KL; Bachireddy P; Zervantonakis IK; Rosenbluth JM; Ouspenskaia T; Law T; Justesen S; Stevens J; Lane WJ; Eisenhaure T; Lan Zhang G; Clauser KR; Hacohen N; Carr SA; Wu CJ; Keskin DB
Nat Biotechnol; 2020 Feb; 38(2):199-209. PubMed ID: 31844290
[TBL] [Abstract][Full Text] [Related]
12. Data-Independent Acquisition of HLA Class I Peptidomes on the Q Exactive Mass Spectrometer Platform.
Ritz D; Kinzi J; Neri D; Fugmann T
Proteomics; 2017 Oct; 17(19):. PubMed ID: 28834231
[TBL] [Abstract][Full Text] [Related]
13. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides.
Kessler JH; Mommaas B; Mutis T; Huijbers I; Vissers D; Benckhuijsen WE; Schreuder GM; Offringa R; Goulmy E; Melief CJ; van der Burg SH; Drijfhout JW
Hum Immunol; 2003 Feb; 64(2):245-55. PubMed ID: 12559627
[TBL] [Abstract][Full Text] [Related]
14. Proteomic identification of an MHC-binding peptidome from pancreas and breast cancer cell lines.
Antwi K; Hanavan PD; Myers CE; Ruiz YW; Thompson EJ; Lake DF
Mol Immunol; 2009 Sep; 46(15):2931-7. PubMed ID: 19615748
[TBL] [Abstract][Full Text] [Related]
15. Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
Murata K; Nakatsugawa M; Rahman MA; Nguyen LT; Millar DG; Mulder DT; Sugata K; Saijo H; Matsunaga Y; Kagoya Y; Guo T; Anczurowski M; Wang CH; Burt BD; Ly D; Saso K; Easson A; Goldstein DP; Reedijk M; Ghazarian D; Pugh TJ; Butler MO; Mak TW; Ohashi PS; Hirano N
Elife; 2020 Apr; 9():. PubMed ID: 32314731
[TBL] [Abstract][Full Text] [Related]
16. High immunogenicity of the human leukocyte antigen peptidomes of melanoma tumor cells.
Jarmalavicius S; Welte Y; Walden P
J Biol Chem; 2012 Sep; 287(40):33401-11. PubMed ID: 22869377
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterisation of peptide binding motifs of six autoimmune disease-associated human leukocyte antigen-class I molecules including HLA-B*39:06.
Eichmann M; de Ru A; van Veelen PA; Peakman M; Kronenberg-Versteeg D
Tissue Antigens; 2014 Oct; 84(4):378-88. PubMed ID: 25154780
[TBL] [Abstract][Full Text] [Related]
18. Identification of MHC class II restricted T-cell-mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides.
Wang M; Tang ST; Stryhn A; Justesen S; Larsen MV; Dziegiel MH; Lewinsohn DM; Buus S; Lund O; Claesson MH
Immunology; 2011 Apr; 132(4):482-91. PubMed ID: 21294723
[TBL] [Abstract][Full Text] [Related]
19. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
20. Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method.
Flad T; Spengler B; Kalbacher H; Brossart P; Baier D; Kaufmann R; Bold P; Metzger S; Blüggel M; Meyer HE; Kurz B; Müller CA
Cancer Res; 1998 Dec; 58(24):5803-11. PubMed ID: 9865739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
